Encephalitis Treatments
Find Encephalitis Treatments
Brand Name
Micafungin
View Brand InformationFDA approval date: August 13, 2018
Classification: Echinocandin Antifungal
Form: Injection
What is Micafungin?
Micafungin for injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies ( 1.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
Brand Information
Micafungin (Micafungin Sodium)
1INDICATIONS AND USAGE
Micafungin for injection is indicated for:
- Treatment of Candidemia, Acute Disseminated Candidiasis,
- Treatment of Candidemia, Acute Disseminated Candidiasis,
- Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older
- Prophylaxis of
Limitations of Use
- The safety and effectiveness of micafungin for injection have
- Micafungin for injection has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to
- The efficacy of micafungin for injection against infections caused by fungi other than
2DOSAGE FORMS AND STRENGTHS
Micafungin for injection, USP is a sterile, white lyophilized powder for reconstitution for intravenous infusion available as:
- 50 mg single-dose vial
- 100 mg single-dose vial
3CONTRAINDICATIONS
Micafungin for injection is contraindicated in persons with known hypersensitivity to micafungin, any component of micafungin for injection, or other echinocandins.
4ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Hypersensitivity Reactions
- Hematological Effects
- Hepatic Effects
- Renal Effects
- Infusion and Injection Site Reactions
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of micafungin cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.
The overall safety of micafungin was assessed in 520 healthy volunteers and 3417 adult and pediatric patients who received single or multiple doses of micafungin across 50 clinical trials, including the invasive candidiasis, esophageal candidiasis and prophylaxis trials. The doses of micafungin administered included doses above and below the recommended doses
4.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of micafungin for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Blood and lymphatic system disorders: disseminated intravascular coagulation
- Hepatobiliary disorders: hepatic disorder
- Renal and urinary disorders: renal impairment
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis
- Vascular disorders: shock
5DRUG ABUSE AND DEPENDENCE
There has been no evidence of either psychological or physical dependence or withdrawal or rebound effects with micafungin.
6OVERDOSAGE
Micafungin is highly protein bound and, therefore, is not dialyzable. No cases of micafungin overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients, up to 6 mg/kg in pediatric patients 4 months of age and older, and up to 15 mg/kg in pediatric patients younger than 4 months of age have been administered in clinical trials with no reported dose-limiting toxicity
7DESCRIPTION
Micafungin for injection, USP is a sterile, lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of
Each single-dose vial contains 50 mg micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg micafungin (equivalent to 101.73 mg micafungin sodium), 200 mg lactose, with citric acid and/or sodium hydroxide (used for pH adjustment). Micafungin for injection, USP must be diluted with 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP
Micafungin sodium is chemically designated as:
Pneumocandin A0,1-[(4
The chemical structure of micafungin sodium is:

The empirical/molecular formula is C
Micafungin sodium is a light-sensitive, hygroscopic white powder that is freely soluble in water, isotonic sodium chloride solution, N,N-dimethylformamide and dimethylsulfoxide, slightly soluble in methyl alcohol, and practically insoluble in acetonitrile, ethyl alcohol (95%), acetone, diethyl ether and n-hexane.
8HOW SUPPLIED/STORAGE AND HANDLING
Micafungin for injection, USP is supplied as a sterile, white lyophilized powder for reconstitution for intravenous infusion in vials coated with a light protective film, and is available as follows:




